Insight Molecular DiagnosticIMDX
13F holders, Q2 2024 (June 30)21holders −2
2new positions
5sold out
1famous investor
$2.95avg. 13F price*
At the end of Q2 2024, 21 institutions reported holding Insight Molecular Diagnostic (IMDX) in their 13F filings, down 2 from Q1 2024. 2 opened new positions and 5 sold out. The largest holders were Broadwood Capital Inc. ($14.5M), Pura Vida Investments, LLC ($1.5M) and Vanguard Group Inc. ($721K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Insight Molecular Diagnostic
- Filed as
- ONCOCYTE CORP (Q2 2024)
- CUSIP
- 68235C206
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $120K |
| Exits | 5 | $1K |
All 13F filers, Q1 2024 → Q2 2024: 2,509,588 shares bought and 78,638 shares sold, net +2,430,950 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 21 holders
| Broadwood Capital Inc. | 1.10% | Add +96.5% | 4,929,066 | $14.5M |
| Pura Vida Investments, LLC | 1.77% | Reduce -5.5% | 495,345 | $1.5M |
| Vanguard Group Inc. | 0.00% | Reduce -1.4% | 244,489 | $721K |
| Geode Capital Management, LLC | 0.00% | Add +48.5% | 92,691 | $273K |
| Morgan Stanley | 0.00% | Reduce -36.1% | 78,696 | $232K |
| BlackRock Inc. | 0.00% | Add +21.0% | 72,827 | $215K |
| FNY Investment Advisers, LLC | 0.05% | New | 23,654 | $69K |
| State Street Corp. | 0.00% | Add +20.0% | 19,554 | $58K |
| Northern Trust Corp. | 0.00% | New | 17,346 | $51K |
| Renaissance Technologies | 0.00% | Reduce -14.7% | 10,418 | $31K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +63.2% | 3,069 | $9K |
| Osaic Holdings, Inc. | 0.00% | Add +1061.9% | 1,127 | $3K |
| UBS Group AG | 0.00% | Reduce -3.4% | 835 | $2K |
| PNC Financial Services Group, Inc. | 0.00% | No change | 500 | $1K |
| Bank of America Corp. | 0.00% | Add +98.1% | 416 | $1K |
| JPMorgan Chase & Co. | 0.00% | No change | 154 | $454 |
| Riggs Asset Managment Co. Inc. | 0.00% | No change | 50 | $148 |
| Piscataqua Savings Bank | 0.00% | No change | 25 | $73 |
| Coppell Advisory Solutions LLC | 0.00% | — | 10 | $30 |
| Albion Financial Group | 0.00% | No change | 7 | $21 |
| Qube Research & Technologies Ltd | 0.00% | No change | 1 | $3 |
"% of holder's portfolio" is IMDX's weight in each manager's 13F, not the share of Insight Molecular Diagnostic the manager owns.